Artivion (AORT) News Today

Artivion, Inc. (NYSE: AORT) stock rose today after a robust second-quarter 2025 report, upwardly revised guidance, and several analyst upgrades.

• Positive Sentiment: Artivion topped Q2 earnings and revenue estimates with EPS of $0.24 vs. $0.11 expected and revenue of $113.0 million vs. $107.96 million. Zacks Earnings Beat
• Positive Sentiment: Revenue grew 15% year-over-year to $113.0 million, and adjusted EBITDA jumped 33% to $24.8 million. PR Newswire Q2 Results
• Positive Sentiment: Q2 EPS surged 243% compared to a year ago. Fool EPS Jump
• Positive Sentiment: Raised FY 2025 revenue guidance to $435.0–$443.0 million vs. $427.4 million consensus. Guidance Update
• Positive Sentiment: Received FDA IDE approval for the ARTIZEN pivotal trial evaluating Arcevo LSA. FDA IDE Approval
• Positive Sentiment: Exchanged $99.5 million of convertible notes for common stock, effectively retiring the debt. Debt Retirement
• Positive Sentiment: JMP Securities raised its price target from $33 to $42 with a “market outperform” rating. JMP Upgrade
• Positive Sentiment: Needham & Company reaffirmed its buy rating and increased its price target from $32 to $45. Needham Rating
• Neutral Sentiment: Stifel Nicolaus raised its price target from $36 to $40, which implies modest downside from current levels. Stifel Price Target
• Neutral Sentiment: Shares recently hit a new 52-week high, reflecting strong market momentum. MarketBeat Alert
• Negative Sentiment: Despite improvements, Artivion still reports a negative net margin of 5.49%. Financial Details